Epilepsy Therapy Project, a nonprofit organization that supports inventors and entrepreneurs to develop new therapies the treatment of epilepsy, is proud to report the successful milestone for ganaxolone, a new epilepsy therapy.
ETP was an early supporter of Marinus Pharmaceuticals, Inc., providing seed funds and introductions that helped the company engage venture capital groups to provide the $30 million needed to reach this stage.
Our seed funding is an example of ETP’s venture philanthropy program: Our goal is to assist start-up companies to move to the next step leading toward a new therapy for epilepsy. Since inception, ETP has provided 33 grants for specific, short-term project, one matching grant, and three seed-stage investments to support start-up companies.
Visit us at www.epilepsy.com/
